Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Kodela Vani"'
Autor:
Seshi R Sompuram, Kodela Vani, Lori Ryan, Corissa Johnson, Matthias Szabolcs, Leonore Peruyero, André Balaton, Sandrine Pierrot, Lija Joseph, Monika Pilichowska, Stephen Naber, Jeffrey Goldsmith, Samantha Green, Steve A Bogen
Publikováno v:
American Journal of Clinical Pathology. 159:274-282
ObjectivesTo evaluate a new US Food and Drug Administration (FDA)–cleared immunohistochemistry (IHC) control (IHControls [Boston Cell Standards]) comprising peptide epitopes for HER2, estrogen receptor (ER), and progesterone receptor (PR) attached
Publikováno v:
Modern Pathology. 35:326-332
Companion diagnostic immunohistochemistry (IHC) tests are developed and performed without incorporating the tools and principles of laboratory metrology. Basic analytic assay parameters such as lower limit of detection (LOD) and dynamic range are unk
Autor:
Kodela Vani, Seshi R. Sompuram, Lili Wang, Emina Torlakovic, Steven A. Bogen, Anika K Schaedle, Paul C. DeRose
Publikováno v:
Cancer Research. 81:PS5-46
Traceability of measurement to a higher order reference standard is a foundation of laboratory testing. There is as yet no method for creating reference standards for cellular proteins in situ in an analogous fashion as for soluble analytes. At prese
Publikováno v:
Modern Pathology. 36:100057
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 35(3)
Companion diagnostic immunohistochemistry (IHC) tests are developed and performed without incorporating the tools and principles of laboratory metrology. Basic analytic assay parameters such as lower limit of detection (LOD) and dynamic range are unk
Autor:
Anika K Schaedle, Steven A. Bogen, Lili Wang, Seshi R. Sompuram, Emina Torlakovic, Paul C. DeRose, Kodela Vani
Publikováno v:
Clin Chem
Background Immunoassays for protein analytes measured in situ support a $2 billion laboratory testing industry that suffers from significant interlaboratory disparities, affecting patient treatment. The root cause is that immunohistochemical testing
Publikováno v:
Archives of Pathology & Laboratory Medicine. 142:851-862
Context.—Numerous studies highlight interlaboratory performance variability in diagnostic immunohistochemistry (IHC) testing. Despite substantial improvements over the years, the inability to quantitatively and objectively assess immunostain sensit
Publikováno v:
Modern Pathology. 34:2242
Publikováno v:
Cancer Research. 81:LB034-LB034
BACKGROUND. The challenges in accurate patient stratification for immune checkpoint inhibitors have been compounded by the fact that the FDA-cleared PD-L1 IHC tests are analytic ‘black boxes'. Relatively basic analytic parameters such as lower limi
Autor:
Kueikwun G Chang, Seshi R. Sompuram, Stephen P. Naber, Monika Pilichowska, Steven A. Bogen, Jeff Goldsmith, Anika K Schaedle, Anuradha Balasubramanian, Kodela Vani, Farzad Noubary
Publikováno v:
Journal of Histochemistry & Cytochemistry. 65:463-477
Clinical Immunohistochemistry (IHC) laboratories face unique challenges in performing accurate and reproducible immunostains. Among these challenges is the use of homemade controls derived from pathological discard samples. Such positive controls hav